Gland Pharma Share Price Jumps to a 52-Week High Despite the Market Sell-Off: Q2 FY27 Profit, CDMO Growth and What to Check

The Gland Pharma share price jumped about 7% to a 52-week high on 9 November 2026 after the company reported a 58% rise in Q2 FY27 profit. This article covers what the results show, what drove the quarter, how the valuation looks after the rally and what to check before reacting. Figures are attributed and time-stamped, and I have no live quote, so verify the current price on NSE or BSE.

Click Here – Get Free Investment Predictions

Gland Pharma Share Price Today: What Moved the Stock to a 52-Week High

Gland Pharma share price: item	Reading	Source
Move reported	Up about 7% to a 52-week high, despite a weak market	Mint headline, 9 November 2026
Open and previous close in the Mint stock widget	Opened at Rs 3,147 against a previous close of Rs 3,132.80	Mint widget as captured
Close on 6 November	Rs 3,169.30, up 0.77%	5paisa data page
52-week range before the move	Rs 1,574 to Rs 3,209	5paisa data page
Trigger	Q2 FY27 results declared after market hours on 6 November	Company filing and press reports

The widget price and the 5paisa close differ because they were captured from different pages at different times, so treat each as a snapshot of the Gland Pharma share price rather than a final print. I have no live index data for the session, so check the Nifty 50 and Sensex pages for the market backdrop that Mint describes as a sell-off.

Gland Pharma Q2 FY27 Results: The Numbers Behind the 52-Week High

Gland Pharma Q2 FY27 results: metric	Q2 FY27	Q2 FY26	Change
Revenue	Rs 1,833.6 crore	Rs 1,486.9 crore	Up 23%
Net profit (PAT)	Rs 290.8 crore	Rs 183.7 crore	Up 58%
EBITDA margin	26%	21%	Up about 5 points (my arithmetic)
Operating profit	Rs 484.04 crore	Not stated in my sources	Up 54.2%
Profit before tax	Rs 430.9 crore	Not stated in my sources	Up 52%
R&D spend	Rs 107.7 crore	Not stated in my sources	About 6% of revenue
CDMO revenue	Rs 8,227 million, or Rs 822.7 crore (my conversion)	Not stated in my sources	Up 31%

For the first half, revenue was Rs 3,633.9 crore, up 21%, and PAT rose 52% to Rs 6,077 million, or about Rs 607.7 crore. One detail the headline does not show: Q1 FY27 PAT was Rs 316.96 crore, so Q2 profit of Rs 290.8 crore was about 8.3% lower than the previous quarter (my arithmetic). Revenue was up about 1.9% on Q1's Rs 1,800.27 crore. The year-on-year jump is real, but the sequential picture is flatter.

Screen pharma stocks by profit growth on the Univest Screener

Gland Pharma 52-Week High: CDMO Growth, USFDA Audits and the CEO Change

Driver behind the Gland Pharma share price	Detail	Status
CDMO growth	Revenue up 31% to Rs 8,227 million	Reported
Margin expansion	EBITDA margin 26% against 21% a year earlier	Reported
Regulatory record	Two facilities audited by the USFDA, one with zero observations	Reported
Leadership	Deepak Sapra takes charge as CEO on 16 November 2026; Shyamakant Giri stepped down on 30 April 2026	Reported
Brokerage view	Nomura raised its EPS estimates and expects a 25x to 30x multiple	Reported; target price not in my sources

Margin expansion on higher CDMO mix is the main operating story behind the 52-week high. A new CEO taking charge a week from now adds a transition variable, which could be positive or neutral; that is my reading, not a company statement. Nomura's multiple range is an analyst view and not a Univest forecast.

Download the Univest iOS App or Univest Android App to track pharma stocks and alerts.

Gland Pharma Share Price Valuation After the Rally

Valuation check on the Gland Pharma share price	Reading	Source and date
Market capitalisation	About Rs 52,297 crore	5paisa, 6 November
P/E and P/B	42.3 and 4.9	5paisa, 6 November
50, 100 and 200-day averages	Rs 2,947.90, Rs 2,755.10 and Rs 2,471.00	5paisa, 6 November
Price against the 200-day average	About 28% above (Rs 3,169.30 against Rs 2,471.00)	My arithmetic
Net worth and ROE	Rs 10,685.7 crore and 11%	Company data via 5paisa
One-month change	Up 5.43%	5paisa, 6 November

A P/E above 40 with an ROE of 11% leaves less room for disappointment, which is why the Gland Pharma share price can react sharply to the next result or regulatory update. The stock trading well above its 200-day average is a feature of strong momentum, not a statement about value.

What to Check Before Acting on the Gland Pharma Share Price Move

Check	Why it matters
Closing price and volume	An intraday spike to a 52-week high can fade by the close
Sequential profit trend behind the Gland Pharma share price 52-week high	Q2 PAT was below Q1, so the year-on-year growth needs context
CDMO order flow behind the Gland Pharma 52-week high	The mix shift drives the margin story
CEO transition from 16 November and the Gland Pharma share price	Strategy continuity is a risk to monitor
Valuation versus growth at a 52-week high	P/E of 42.3 needs sustained earnings growth

Conclusion

The Gland Pharma share price reached a 52-week high because Q2 FY27 profit rose 58%, margins widened to 26% and CDMO revenue grew 31%. The quarter was softer than Q1 on profit and the valuation is not low, so the rally already reflects good news. Check the close, read the earnings call and consult a SEBI-registered adviser before acting.

Frequently Asked Questions on the Gland Pharma Share Price

Why did the Gland Pharma share price hit a 52-week high?

Ans. Mint reported that the shares rose about 7% to a 52-week high after Q2 FY27 results showed PAT up 58% to Rs 290.8 crore, revenue up 23% to Rs 1,833.6 crore and an EBITDA margin of 26% against 21%. The results were declared after market hours on 6 November, so 9 November was the first session to price them in.

What were Gland Pharma's Q2 FY27 results behind the Gland Pharma share price rise?

Ans. Revenue was Rs 1,833.6 crore against Rs 1,486.9 crore, PAT was Rs 290.8 crore against Rs 183.7 crore, operating profit was Rs 484.04 crore, up 54.2%, and PBT was Rs 430.9 crore, up 52%. R&D spend was Rs 107.7 crore, about 6% of revenue.

Did Gland Pharma's profit fall from the previous quarter before the 52-week high?

Ans. Yes. Q1 FY27 PAT was Rs 316.96 crore, so Q2 PAT of Rs 290.8 crore was about 8.3% lower on a sequential basis, by my arithmetic. Revenue rose about 1.9% from Rs 1,800.27 crore. Year-on-year growth remains strong because Q2 FY26 PAT was only Rs 183.7 crore.

Who is the new CEO of Gland Pharma after the 52-week high?

Ans. Deepak Sapra takes charge as CEO on 16 November 2026. Shyamakant Giri stepped down on 30 April 2026. Leadership changes can affect strategy and investor sentiment, so management commentary after the handover is worth following.

What is the 52-week range of the Gland Pharma share price?

Ans. 5paisa showed a 52-week low of Rs 1,574 and a high of Rs 3,209 as of 6 November 2026. A move to a new 52-week high means the stock traded above that Rs 3,209 level, so check a live quote for the current range.

What is the valuation of Gland Pharma after the rally?

Ans. 5paisa data from 6 November showed a market capitalisation of about Rs 52,297 crore, a P/E of 42.3 and a P/B of 4.9, with ROE at 11%. The stock was about 28% above its 200-day average, by my arithmetic. These are pre-rally figures for the 9 November move.

What do analysts say about the Gland Pharma share price?

Ans. Nomura raised its EPS estimates and expects a 25x to 30x multiple, per the reports I reviewed. I did not find a verified target price, so none is quoted. Analyst views differ and are not a forecast by Univest.

Should I buy Gland Pharma shares at a 52-week high?

Ans. Univest cannot give personal advice and does not recommend any security. A 52-week high reflects momentum, not value, and the P/E is above 40. Review the results, valuation and your risk tolerance, and consult a SEBI-registered adviser.